Fauzia Ullah
Overview
Explore the profile of Fauzia Ullah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kawashima N, Gurnari C, Bravo-Perez C, Kubota Y, Pagliuca S, Guarnera L, et al.
Leukemia
. 2024 Nov;
39(2):451-459.
PMID: 39572711
Past studies described occasional patients with myeloid neoplasms (MN) and coexistent large granular lymphocytic leukemia (LGLL) or T-cell clonopathy of unknown significance (TCUS), which may represent expansion of myeloid clonal...
2.
Gordon J, Bravo-Perez C, Guarnera L, Unlu S, Kawashima N, Ahmed A, et al.
Blood Cancer J
. 2024 Jul;
14(1):125.
PMID: 39080258
No abstract available.
3.
Dima D, Lopetegui-Lia N, Ogbue O, Osantowski B, Ullah F, Jia X, et al.
Cancer Med
. 2024 Jul;
13(12):e7257.
PMID: 39031560
Background: Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real-world outcomes are limited. In addition, a significant proportion...
4.
Dima D, Hughes M, Orland M, Ullah F, Goel U, Anwer F, et al.
Amyloid
. 2024 Jul;
31(3):195-201.
PMID: 38956891
Background: Daratumumab's incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have suboptimal response...
5.
Lin C, Tariq M, Ullah F, Sannareddy A, Khalid F, Abbas H, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892379
Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal...
6.
Dima D, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, et al.
Hematol Oncol
. 2024 Jun;
42(4):e3293.
PMID: 38872511
Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell-directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the...
7.
Wesson W, Dima D, Suleman N, Saif M, Tabak C, Logan E, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):876-884.
PMID: 38871056
BCMA-directed chimeric antigen receptor T-cell (CAR T) therapies, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have transformed the treatment landscape for relapsed-refractory multiple myeloma (RRMM), offering remarkable efficacy with...
8.
Awada H, Durmaz A, Kewan T, Ullah F, Dima D, Awada H, et al.
Leukemia
. 2024 May;
38(6):1411-1414.
PMID: 38734787
No abstract available.
9.
Orland M, Ullah F, Yilmaz E, Geiger J
JCO Oncol Pract
. 2024 May;
20(12):1588-1595.
PMID: 38709998
Despite significant progress and improving outcomes in the management of head and neck squamous cell carcinoma (HNSCC), there are few effective treatment options for patients with recurrent or metastatic head...
10.
Ullah F, Markouli M, Orland M, Ogbue O, Dima D, Omar N, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610985
Large granular lymphocytic (LGL) leukemia is a lymphoproliferative disorder characterized by persistent clonal expansion of mature T- or natural killer cells in the blood via chronic antigenic stimulation. LGL leukemia...